Literature DB >> 26508007

Specific K39 antibody response and its persistence after treatment in patients with imported leishmaniasis.

Ingrid Reiter-Owona1, Claudia Rehkaemper-Schaefer2, Sandra Arriens3, Philip Rosenstock4, Kenneth Pfarr3, Achim Hoerauf3.   

Abstract

The sensitivity of a K39 ELISA (Leishmania IgG, Virion/Serion) for the detection of antibodies in patients with imported leishmaniasis was compared with an immunofluorescence assay (IFA), which was applied as "golden standard". The retrospective study comprised 93 IFA-positive or borderline sera from 42 patients with visceral (n = 16) or cutaneous (n = 26) leishmaniasis. Patients had acquired infection predominately in the Mediterranean area or the Middle East. The Leishmania species (Leishmania donovani/infantum, Leishmania tropica, Leishmania major) were identified by real-time PCR. The majority (94%) of first samples from patients with visceral leishmaniasis (VL) tested positive by K39 ELISA. Antibody levels ranged from low to very high (33.19-1990.00 U/ml; median 596.66 U/ml) but did not correlate with the respective IFA titers. High K39 ELISA values correlated with acute infection in immunocompetent individuals. K39 antibodies declined in all individuals after clinically successful therapy, but time to seronegativity varied considerably (51 weeks to >6 years). In patients with cutaneous leishmaniasis (CL), the sensitivity of the K39 ELISA was low (23%) compared to IFA (92% positive). Antibody levels ranged from low to medium (10.85-524.77 U/ml; median 19.77 U/ml). The highest antibody concentrations were seen in L. infantum-infected individuals. Summarizing, a high K39 ELISA value indicates active VL. The assay is, like IFA, not a measure for effective therapy but may support post-treatment monitoring. Low level positivity can indicate subclinical, previous or clinically cured VL or even CL. The K39 ELISA can supplement highly sensitive screening tests in the diagnosis and follow-up of imported leishmaniasis.

Entities:  

Keywords:  Diagnosis; IFA; Imported leishmaniasis; K39 ELISA; Leishmaniasis; Treatment

Mesh:

Substances:

Year:  2015        PMID: 26508007      PMCID: PMC4722063          DOI: 10.1007/s00436-015-4801-8

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  25 in total

1.  Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis.

Authors:  Ibtissem Abdmouleh Maalej; Mehdi Chenik; Hechmi Louzir; Afif Ben Salah; Chokri Bahloul; Fethi Amri; Koussay Dellagi
Journal:  Am J Trop Med Hyg       Date:  2003-03       Impact factor: 2.345

2.  Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis.

Authors:  A C Vallur; A Hailu; D Mondal; C Reinhart; H Wondimu; Y Tutterrow; H W Ghalib; S G Reed; M S Duthie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-19       Impact factor: 3.267

3.  Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network.

Authors:  T Weitzel; N Mühlberger; T Jelinek; M Schunk; S Ehrhardt; C Bogdan; K Arasteh; T Schneider; W V Kern; G Fätkenheuer; G Boecken; T Zoller; M Probst; M Peters; T Weinke; S Gfrörer; H Klinker; M-L Holthoff-Stich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-07       Impact factor: 3.267

4.  A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy.

Authors:  R L Houghton; M Petrescu; D R Benson; Y A Skeiky; A Scalone; R Badaró; S G Reed; L Gradoni
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

5.  Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.

Authors:  Gustavo Adolfo Sierra Romero; Maria de la Glória Orge Orge; Marcus Vinitius de Farias Guerra; Marcilene Gomes Paes; Vanize de Oliveira Macêdo; Edgar M de Carvalho
Journal:  Acta Trop       Date:  2005-01       Impact factor: 3.112

6.  Antibody responses in patients with cutaneous leishmaniasis of the Old World.

Authors:  S Menzel; U Bienzle
Journal:  Tropenmed Parasitol       Date:  1978-06

7.  Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis.

Authors:  J M Burns; W G Shreffler; D R Benson; H W Ghalib; R Badaro; S G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

8.  Application of a direct agglutination test for detection of specific anti-Leishmania antibodies in the canine reservoir.

Authors:  A el Harith; R J Slappendel; I Reiter; F van Knapen; P de Korte; E Huigen; A H Kolk
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

9.  Heterogeneity of Leishmania donovani parasites complicates diagnosis of visceral leishmaniasis: comparison of different serological tests in three endemic regions.

Authors:  Elfadil Abass; Cholho Kang; Franjo Martinkovic; Saul J Semião-Santos; Shyam Sundar; Peter Walden; Renaud Piarroux; Abdallah El Harith; Michael Lohoff; Ulrich Steinhoff
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

10.  Leishmaniasis in Germany.

Authors:  Gundel Harms; Gabriele Schönian; Hermann Feldmeier
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  5 in total

1.  Diagnosing Cutaneous leishmaniasis using Fluorescence in Situ Hybridization: the Sri Lankan Perspective.

Authors:  Thilini Dilhara Jayasena Kaluarachchi; Manjula Manoji Weerasekera; Andrew J McBain; Shalindra Ranasinghe; Renu Wickremasinghe; Surangi Yasawardene; Nisal Jayanetti; Rajitha Wickremasinghe
Journal:  Pathog Glob Health       Date:  2019-08-20       Impact factor: 2.894

2.  ELISA-based evaluation of antibody response to Leishmania in a region endemic for cutaneous leishmaniasis.

Authors:  Sachee Bhanu Piyasiri; Thisum Nilakshi Samaranayake; Hermali Silva; Nuwani Harshamali Manamperi; Nadira Darshani Karunaweera
Journal:  Parasite Immunol       Date:  2022-08-03       Impact factor: 2.206

3.  Design and characterization of high-affinity synthetic peptides as bioreceptors for diagnosis of cutaneous leishmaniasis.

Authors:  Y Andrea Prada; Maria Soler; Fanny Guzmán; John J Castillo; Laura M Lechuga; Enrique Mejía-Ospino
Journal:  Anal Bioanal Chem       Date:  2021-05-26       Impact factor: 4.142

4.  Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India.

Authors:  Sarfaraz Ahmad Ejazi; Pradyot Bhattacharya; Md Asjad Karim Bakhteyar; Aquil Ahmad Mumtaz; Krishna Pandey; Vidya Nand Ravi Das; Pradeep Das; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  PLoS Negl Trop Dis       Date:  2016-10-14

5.  Isolation and characterisation of Leishmania donovani protein antigens from urine of visceral leishmaniasis patients.

Authors:  Tegwen Marlais; Tapan Bhattacharyya; Callum Pearson; Bathsheba L Gardner; Safiyyah Marhoon; Stephanie Airs; Kiera Hayes; Andrew K Falconar; Om Prakash Singh; Steven G Reed; Sayda El-Safi; Shyam Sundar; Michael A Miles
Journal:  PLoS One       Date:  2020-09-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.